BRPI0417759A - combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso - Google Patents

combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso

Info

Publication number
BRPI0417759A
BRPI0417759A BRPI0417759-2A BRPI0417759A BRPI0417759A BR PI0417759 A BRPI0417759 A BR PI0417759A BR PI0417759 A BRPI0417759 A BR PI0417759A BR PI0417759 A BRPI0417759 A BR PI0417759A
Authority
BR
Brazil
Prior art keywords
methyl
pyrimidine
pyridyl
amine
combination
Prior art date
Application number
BRPI0417759-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Tim H Bruemmendorf
Stefan Balabanov
Ulrike Hartmann
Winfried Kammer
Alfred Nordheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0417759A publication Critical patent/BRPI0417759A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0417759-2A 2003-12-19 2004-12-17 combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso BRPI0417759A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19
PCT/EP2004/014439 WO2005058320A1 (en) 2003-12-19 2004-12-17 COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF

Publications (1)

Publication Number Publication Date
BRPI0417759A true BRPI0417759A (pt) 2007-04-10

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417759-2A BRPI0417759A (pt) 2003-12-19 2004-12-17 combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso

Country Status (17)

Country Link
US (1) US20080139480A1 (enExample)
EP (1) EP1696917A1 (enExample)
JP (1) JP2007514699A (enExample)
KR (1) KR20060125810A (enExample)
CN (1) CN1889952A (enExample)
AU (2) AU2004298761A1 (enExample)
BR (1) BRPI0417759A (enExample)
CA (1) CA2547196A1 (enExample)
EC (1) ECSP066656A (enExample)
IL (1) IL176070A0 (enExample)
MA (1) MA28240A1 (enExample)
MX (1) MXPA06006925A (enExample)
NO (1) NO20063326L (enExample)
RU (1) RU2006125741A (enExample)
TN (1) TNSN06182A1 (enExample)
WO (1) WO2005058320A1 (enExample)
ZA (1) ZA200603904B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027473A1 (en) 2007-08-31 2009-03-05 Janssen Pharmaceutica Nv Combinations of imazalil and hydroxypyridones
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
EP2252147B1 (en) 2008-02-06 2012-12-05 Janssen Pharmaceutica NV Combinations of fludioxonil and pyrion compounds
EP2242365B1 (en) * 2008-02-06 2013-01-16 Janssen Pharmaceutica NV Combinations of pyrimethanil and pyrion compounds
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
CN103153309A (zh) * 2010-06-01 2013-06-12 拜欧赛里克斯公司 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
US8691834B2 (en) 2010-06-10 2014-04-08 Janssen Pharmaceutica Nv Combinations of pyrimethanil and monoterpenes
CN102958366B (zh) 2010-07-01 2015-02-11 詹森药业有限公司 pyrion化合物与聚乙烯亚胺的抗微生物组合
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
ES2331562T3 (es) * 2001-03-23 2010-01-08 Enzon, Inc. Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Also Published As

Publication number Publication date
AU2004298761A1 (en) 2005-06-30
CA2547196A1 (en) 2005-06-30
NO20063326L (no) 2006-09-19
US20080139480A1 (en) 2008-06-12
MXPA06006925A (es) 2006-08-23
ZA200603904B (en) 2007-09-26
TNSN06182A1 (en) 2007-11-15
RU2006125741A (ru) 2008-01-27
MA28240A1 (fr) 2006-10-02
CN1889952A (zh) 2007-01-03
EP1696917A1 (en) 2006-09-06
WO2005058320A1 (en) 2005-06-30
AU2009201694A1 (en) 2009-05-28
IL176070A0 (en) 2006-10-05
KR20060125810A (ko) 2006-12-06
JP2007514699A (ja) 2007-06-07
ECSP066656A (es) 2006-10-25

Similar Documents

Publication Publication Date Title
BR0209647A (pt) Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
BR0308053A (pt) Stents revestidos com n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
BRPI0417759A (pt) combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
AU2003259521A8 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
AU2003233946A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
DE60235499D1 (de) ZELLWACHSTUMSHEMMER MIT ANTI-PepT-ANTIKÖRPER
DE602006015994D1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
EP1704863A3 (en) Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
DE60304678D1 (de) Idraparinux (sanorg 34006) zur behandlung und sekundärprophylaxe von thromboembolien bei patienten mit tiefer venenthrombose
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
JP2005508846A5 (enExample)
NZ610401A (en) Inhibitors of the mutant form of kit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.